WO2010108314A1 - Use of fiber pentose or composition containing fiber pentose in manufacture of foods or medicines for preventing and/or treating acidification in diabetic patient - Google Patents

Use of fiber pentose or composition containing fiber pentose in manufacture of foods or medicines for preventing and/or treating acidification in diabetic patient Download PDF

Info

Publication number
WO2010108314A1
WO2010108314A1 PCT/CN2009/070959 CN2009070959W WO2010108314A1 WO 2010108314 A1 WO2010108314 A1 WO 2010108314A1 CN 2009070959 W CN2009070959 W CN 2009070959W WO 2010108314 A1 WO2010108314 A1 WO 2010108314A1
Authority
WO
WIPO (PCT)
Prior art keywords
pentose
fiber
liquid mixture
cellulose
acid
Prior art date
Application number
PCT/CN2009/070959
Other languages
French (fr)
Chinese (zh)
Inventor
孙萌
朱作霖
苏春高
叶红平
Original Assignee
淮北中润生物能源技术开发有限公司
美国升阳制药公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 淮北中润生物能源技术开发有限公司, 美国升阳制药公司 filed Critical 淮北中润生物能源技术开发有限公司
Priority to PCT/CN2009/070959 priority Critical patent/WO2010108314A1/en
Publication of WO2010108314A1 publication Critical patent/WO2010108314A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/02Monosaccharides
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51Thiamines, e.g. vitamin B1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/02Monosaccharides

Definitions

  • a fiber pentose or a fiber pentose-containing composition for the preparation of a food or a medicament for preventing and/or treating acidification of a body of a diabetic patient
  • the present invention relates to the field of cellulosic biomass, and more particularly to a composition for controlling acidification of a body of a diabetic patient. Background technique
  • Diabetes is a disease in which the body cannot secrete insulin, or the amount of insulin secreted or/and the quality of insulin is insufficient, causing the body to be unable to effectively degrade metabolic glucose.
  • people with diabetes generally use more protein and so on to provide the body with the necessary energy supply. Since the metabolism of substances such as proteins is not the most suitable way to supply energy to the body, a large amount of this metabolism causes incomplete metabolism, and since most protein molecules contain many heteroatoms such as nitrogen, sulfur, and phosphorus, etc., The cumulative result is the acidification of the body.
  • Acidification of the body is a common phenomenon in patients with diseases and the elderly.
  • the bodies of healthy people and adolescents are all slightly alkaline.
  • many high-activity particles such as free radicals are more easily produced, which raises the body's oxidative stress level, and abnormal oxidative stress is the most fundamental cause of various cell damage and death in the body, abnormal levels.
  • Oxidative stress is thought to be an important cause of chronic complications of diabetes and diabetes, pulmonary fibrosis, epilepsy, hypertension, atherosclerosis and corresponding cardiovascular diseases, cancer, nephropathy, and Parkinson's disease.
  • many patients, such as cancer patients are basically acidic, maintaining the body in a slightly alkaline state, which is one of the important means to reduce the level of oxidative stress.
  • the acidity and alkalinity of foods are not determined by mouthfeel, but by the results of digestion and absorption of food in the body. If there are more anions such as phosphate, sulfate, nitrate, and chloride ions produced after food metabolism, it will cause acidification of the body and be an acidic food. If the food is metabolized, sodium ions, potassium ions, magnesium ions, and calcium are produced. If there are many ionic plasmas, it is easy to cause alkalization of the body and it is an alkaline food. Although citric acid and so on are acidic, human metabolism converts it into water and carbon dioxide. It is a neutral food.
  • Protein has no acid-base taste, but the body metabolizes it to produce anions such as sulfate, nitrate and chloride. It is an acidic food; the final metabolites of carbohydrates are water and carbon dioxide. It can be seen that when a diabetic patient becomes a subject, the body of the food is converted from carbohydrate to protein, and the body is highly susceptible to acidification, resulting in a further increase in oxidative stress.
  • natural five-carbon sugar is an ideal glucose replacement sugar, a substance that provides sugar source energy for diabetic patients and restores diabetes. Eating habits can eat sugar.
  • their use in life is limited for two reasons. First, the degree of absorption of five carbon sugars in the body is low, It is because their production costs are too high and most people are unlikely to consume.
  • the present invention is directed to the use of a fiber pentose or a composition comprising a fiber pentose.
  • Another object of the present invention is to provide a process for preparing pure xylose from cellulosic biomass.
  • a pentose pentose or a pentose-containing composition for the preparation of a food or medicament for preventing and/or treating acidification of a body of a diabetic patient.
  • the fiber pentose-containing composition is composed of a fiber pentose sugar and a substance which promotes absorption of the fiber pentose sugar in the body.
  • a sugar absorption enhancer is selected from one or more of the following: cellulose, vitamin B1, vitamin B5, vitamin B6, thyroxine, adrenaline, potassium ion, Magnesium ions, sodium ions.
  • it contains: 100 parts by weight of pentose sugar; and 0.001 - 99 parts by weight of a sugar absorption enhancer, based on 100 parts by weight of the composition.
  • the weight ratio of the pentose sugar to the sugar absorption enhancer is 0.001.
  • the substance for promoting absorption of the fiber pentose in the body includes all substances which promote the absorption of the fiber pentose in the body, and may be a macromolecular substance, a small molecule substance or even an ion. , including but not limited to cellulose, vitamin B1, vitamin B5, vitamin B6, thyroxine, adrenaline, potassium, magnesium, sodium, and the like.
  • the cellulose comprises all of the cellulose, preferably microcrystalline cellulose, most preferably nano-sized cellulose.
  • the fiber pentose sugar is selected from one or more of the following: xylose, ribose, arabinose, lyxose, nucleoside Ribulose, xylulose.
  • the fiber pentose is obtained by the following steps:
  • the fiber pentose is obtained by the following steps:
  • the cellulose-containing biomass, water and catalyst are mixed at 30-18 CTC for 3 to 600 minutes, and hydrolyzed to obtain a liquid mixture I;
  • the catalyst is selected from the group consisting of: hemicellulose hydrolase, organic acid, inorganic acid, or a biomimetic catalyst;
  • the organic acid is selected from the group consisting of: an organic acid containing less than 20 carbons;
  • the inorganic acid is selected from the group consisting of: sulfuric acid, hydrochloric acid, and phosphoric acid;
  • the biomimetic catalyst is selected from the group consisting of [CpFeCO (maleic acid)] BF4 Or iron bis(diamine diacetate) complex;
  • the fiber pentose contains 1 to 90% by weight of arabinose, based on the total weight of the fiber pentose ; preferably, the fiber pentose contains 5-25% by weight of the arabinose.
  • the fiber pentose is obtained by the following steps:
  • the fiber pentose is obtained by the following steps:
  • the cellulose-containing biomass, water and catalyst are mixed at 90-18 CTC for 30-120 minutes, and hydrolyzed to obtain a liquid mixture I;
  • the catalyst is selected from the group consisting of: hemicellulose hydrolase, organic acid, inorganic acid, or a biomimetic catalyst;
  • the organic acid is selected from the group consisting of: an organic acid containing less than 20 carbons;
  • the inorganic acid is selected from the group consisting of: sulfuric acid, hydrochloric acid, and phosphoric acid;
  • the biomimetic catalyst is selected from the group consisting of: [CpFeCO (maleic acid)] BF4, or iron diammonium diacetate complex;
  • the food product comprises a solid food and a liquid food.
  • a method of preparing pure xylose from cellulosic biomass comprising the steps of: recrystallizing a fiber pentose sugar through a simple ethanol/water mixed solvent; Pentose is obtained by the following steps:
  • the cellulose-containing biomass, water and catalyst are mixed at 90-18 CTC for 30-120 minutes, and hydrolyzed to obtain a liquid mixture I;
  • the catalyst is selected from the group consisting of: hemicellulose hydrolase, organic acid, inorganic acid, or a biomimetic catalyst;
  • the organic acid is selected from the group consisting of: an organic acid containing less than 20 carbons;
  • the inorganic acid is selected from the group consisting of: sulfuric acid, hydrochloric acid, and phosphoric acid;
  • the biomimetic catalyst is selected from the group consisting of: [CpFeCO (maleic acid)] BF4, or iron diammonium diacetate complex;
  • the liquid mixture I I is ion-exchanged to obtain a fiber pentose. Accordingly, the present invention provides a substance containing natural five-carbon sugar, which has a high degree of absorption in the body, can effectively prevent acidification of a body of a diabetic patient, and has low production cost.
  • Fiber pentose when mixed with other substances, can greatly enhance natural five-carbon sugar in the body.
  • the effective absorption can provide a source of sugar energy for diabetic patients, preventing the acidification of the body caused by long-term use of protein as an energy substance in diabetic patients, thereby reducing oxidative stress and preventing diseases.
  • cellulose-containing biomass and “cellulose-containing biomass” are used interchangeably and refer to all cellulose-containing materials, including cellulose biomass in the traditional definition, including plants.
  • the seeds, fruits, stems, leaves, and roots even include some microorganisms.
  • the plants include all non-toxic plants, and the properties of the product are not affected by the source of the plant.
  • All cellulose-containing biomass may be used, preferably a hemicellulose content of 5% by weight or more based on the total weight of the cellulosic biomass, most preferably a hemicellulose content of 10 wt% based on the total weight of the cellulosic biomass. More than % of the substance.
  • cellulosic biomass refers to biomass containing cellulose, hemicellulose, and lignin as a major component, and generally does not include the fruits of plants.
  • Microcrystalline cellulose is a pure natural cellulose depolymerization product, which is in the form of fine powder, white, odorless, tasteless; composed of free-flowing crystalline powder (non-fibrous particles). Insoluble in water, diluted acid and most organic solvents, slightly soluble in 20% alkali solution. It can be directly used for dry powder tableting, and is widely used as a pharmaceutical excipient, a flow aid, a filler, a disintegrant, an anti-adhesive agent, an adsorbent, a capsule diluent, and the like.
  • Nanocrystalline cellulose in the present invention refers to a cellulosic material having a cross-sectional length of 10 to 20 nm and a fiber length of less than 100 nm.
  • the fiber pentose sugar is selected from all natural five carbon sugars, such as xylose, ribose, arab inose, lyxose, and pentoketone.
  • the pentose sugar may be either a single pure five-carbon sugar or a mixture thereof, and the content of each sugar in the mixture is not limited.
  • "fibrous pentose”, "natural five-carbon sugar composition” or “natural five-carbon sugar” can be interchanged. Use, all refer to all naturally occurring monosaccharides containing five carbon atoms in nature, or simply derivatives or polymers thereof.
  • mametic catalyst refers to a synthetic catalyst containing at least one catalytic domain and a cel lulose binding domain, such as [CpFeCO (maleic acid)] BF4, Iron complex of ethylene diamine diacetate, and the like.
  • the biomimetic catalyst is described in detail in the patent application PCT/CN/2007/071114, the entire disclosure of which is incorporated herein by reference.
  • the pentose sugar of the present invention can be obtained by the following steps:
  • the fiber pentose is obtained by the following steps:
  • the pulverized cellulose-containing biomass is dewaxed using near-boiling water (80-98 ° C, preferably 90-95 ° C);
  • the dewaxed cellulose-containing biomass and catalyst are mixed at 30-14 CTC for 3 - 600 minutes, hydrolyzed, and solid-liquid separated to obtain a liquid mixture I;
  • the catalyst is selected from the group consisting of: hemicellulose hydrolase
  • the organic acid, the inorganic acid, or the biomimetic catalyst is selected from the group consisting of: an organic acid containing less than 20 carbons;
  • the inorganic acid is selected from the group consisting of: sulfuric acid, hydrochloric acid, and phosphoric acid;
  • the biomimetic catalyst is selected from the group consisting of: Patent application PCT/CN/2007/071114;
  • the catalyst is separated or inactivated;
  • the separation comprises passing the liquid mixture I through the macroporous adsorption resin;
  • the inactivation comprises heating, neutralization, etc.;
  • the liquid mixture I and the alcohol yeast are mixed at 20-60 ° C for 6 to 48 hours, and the solid is filtered to obtain a liquid product ⁇ ;
  • the liquid product I I is subjected to ion exchange to obtain a fiber pentose solution.
  • the ion exchange in the fifth step includes cation exchange, and anion exchange, and sometimes in order to improve the quality of the product, a mixed column containing both a cationic resin and an anionic resin is added. Elution Generally, pure water is used, and the regeneration of the exchange resin is generally an aqueous solution of sodium hydroxide and dilute hydrochloric acid.
  • the composition for preventing acidification of a body of a diabetic patient provided by the invention comprises a fiber pentose sugar and a pentose sugar absorption enhancer; wherein the sugar absorption enhancer is selected from one or more of the following substances: cellulose, vitamin B, Vitamin B5, vitamin B6, thyroxine, adrenaline, potassium ion, magnesium ion, sodium ion.
  • the weight ratio of the weight of the pentose saccharide and the sugar absorbing agent, such as the microcrystalline cellulose is 0. 001 - 1000: 1 , preferably 0. 015 - 10: 1, more preferably 0. 02 - 0. : 1
  • the composition provided by the present invention can be obtained by mixing a fiber pentose with one or more substances selected from the group consisting of cellulose, vitamin B1, vitamin B5, vitamin B6, thyroxine, adrenaline, potassium ion, magnesium. Ions, sodium ions. Mixing, including conventional mixing, co-crystallization, co-drying, said vitamins, thyroxine, adrenaline, potassium ions, magnesium ions, sodium ions, etc., in the composition is the highest safe level they allow.
  • the substance for enhancing the absorption of the five-carbon sugar in the present invention includes cellulose, vitamin B1, vitamin B5, vitamin B6, thyroxine, adrenaline, potassium ion, magnesium ion, sodium ion, and the like.
  • the cellulose is present in the composition in an amount between 1% and 99%.
  • a method of producing a composition of the invention comprising the steps of:
  • the hydrolysis catalyst is generally a hemicellulose hydrolase, an organic acid, a mineral acid, and a biomimetic catalyst;
  • the fiber pentose or the fiber pentose-containing composition provided by the present invention can be used for the preparation of a product for preventing and/or treating the acidification of a body of a diabetic patient, which can be a general food, a health food, or a medicine.
  • the fiber pentose or the fiber pentose-containing composition provided by the present invention can also be used for the preparation of a drug for promoting the absorption of pentose sugar, and particularly for the preparation of a drug for promoting the absorption of arabinose.
  • the drug can be obtained by mixing the fiber pentose or the fiber pentose-containing composition provided by the present invention with a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier refers to a carrier for the administration of a therapeutic agent, Various excipients and diluents are included. The term refers to pharmaceutical carriers which are not themselves essential active ingredients and which are not excessively toxic after administration. Suitable carriers are well known to those of ordinary skill in the art. A full discussion of pharmaceutically acceptable excipients can be found in Remi ngton's Pharmac eut i cal Sc i enc es (Mack Pub. Co., NJ 1991). Pharmaceutically acceptable carriers in the compositions may include liquids such as water, saline, glycerol and ethanol. In addition, auxiliary substances such as disintegrants, wetting agents, emulsifiers, pH buffering substances and the like may also be present in these carriers.
  • the medicament may be prepared into various dosage forms, such as a solid preparation, or a liquid preparation, depending on the administration route. These dosage forms are administered in one of the following ways: oral, spray inhalation, rectal administration, nasal administration, buccal administration, topical administration, parenteral administration, such as subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal And intracranial injection or input, or with an explant reservoir.
  • the present invention provides a product for preventing acidification of a body of a diabetic patient, and more particularly to provide a natural five-carbon sugar monomer or a composition therebetween, and at the same time, to provide a body capable of promoting five-carbon sugar by the body.
  • the method of absorption allows diabetic patients to still use the energy of sugar source, help prevent acidification of the body of diabetic patients, reduce the level of oxidative stress, and prevent chronic complications of diabetes.
  • Natural five-carbon sugars are found in virtually all cellulose-containing biomass, including cellulosic biomass, including their seeds, fruits, stems, leaves, roots, and the like. These polymers of pentose sugars are more easily hydrolyzed into monosaccharides during the production of food. Their metabolism in the body does not require the participation of insulin, which can stimulate the health and development of other functions of the body, while at the same time reducing the islets of the islets. Work stress is very important to maintain the health of the human body.
  • the proportion of finishing in human food is increasing, and the intake of these natural five-carbon sugars is greatly reduced.
  • humans are trying to supplement, such as the preparation of fruit vinegar and other products in order to increase the body's natural five-carbon sugar intake, but due to the influence of human diet, the population of such products is very small. Therefore, the natural five-carbon sugar composition provided in the present invention is also of great significance to the average consumer. Since natural arabinose has been shown to be the worst-absorbing five-carbon sugar in the research results to date, the present invention is exemplified by natural arabinose. It is to be understood that natural arabinose is used as an example to better illustrate the invention and is not intended to limit the scope of the invention.
  • the product provided by the invention effectively reduces the acidification of the body of a diabetic patient
  • the product provided by the invention can restore the normal living habits of diabetic patients
  • composition provided by the invention can effectively promote the absorption of five carbon sugars in the body
  • the invention achieves low cost of obtaining natural five-carbon sugar.
  • the invention is further illustrated below in conjunction with specific embodiments. It is to be understood that the examples are not intended to limit the scope of the invention.
  • the experimental methods in which the specific conditions are not indicated in the following examples are usually carried out according to conventional conditions or according to the conditions recommended by the manufacturer. All percentages, ratios, ratios, or parts are by weight unless otherwise indicated.
  • the unit of weight percent by volume in the present invention is well known to those skilled in the art and, for example, refers to the weight of the solute in a 100 ml solution.
  • the 5% of the bean cake powder is added after the 5% of the bean cake powder is added to the 5% of the bean cake powder.
  • Liquid products are ion exchanged (732-cation exchange resin column, 721 - anion exchange resin column, and mixed bed ion exchange column), concentrated to sugar content (total sugar content, including all five carbon sugars, using Abbe refractometer, Accurate quantification by liquid chromatography) Approximately 50% aqueous solution, wherein the arabinose content is about 12%, and the total liquid product obtained is 260 ml. The HPLC chromatogram of the product only detects arabinose and xylose, and the six carbon sugar does not. Observed. The preparation was repeated several times to obtain sufficient solid product preparation.
  • HPLC Liquid Chromatography
  • the flow rate is 1 ml / min
  • the refractive index detector the retention time of ribose is about 5.8 minutes
  • the retention time of xylose is 6. 6 ⁇
  • the retention time of the arabinose is about 7.3 minutes
  • the retention time of the fructose is about 8.2 minutes
  • the retention time of the glucose is about 7.9 minutes
  • the retention time of the galactose is about 10. 2 minutes.
  • Example 1B If it is necessary to prepare a solid product, it can be obtained by lyophilization (135 g of a solid product obtained by lyophilization, water content of 2%) or by spray drying; if it is necessary to prepare a liquid product, the package can be sealed under inert gas protection.
  • lyophilization (135 g of a solid product obtained by lyophilization, water content of 2%) or by spray drying; if it is necessary to prepare a liquid product, the package can be sealed under inert gas protection.
  • the 5% of the bean cake powder is added after the 5% of the bean cake powder is added to the 5% of the bean cake powder.
  • 1% high-efficiency Anqi dry yeast was added and fermented at 34 °C for 24 hours. Sampling and detection, HPLC analysis method is basically undetectable. After the yeast is inactivated by heating, the solid-liquid separation is carried out by filtration to obtain a liquid product.
  • the liquid product is ion exchanged (732-cation exchange resin column, 721 - anion exchange resin column, and mixed bed ion exchange column), and concentrated to a sugar content (total sugar content, using an Abbe refractometer) of about 50%, wherein The arabinose content is about 53%, and the total liquid product (ie, fiber pentose) is 380.
  • the freeze-dried fiber pentose solid product ie, fiber pentose I
  • microcrystalline cellulose are mixed to make the content of microcrystalline cellulose 10%, 20%, 30%, 40%, and they are used to feed half.
  • the old monkey the monkey's living environment is manually controlled 12 hours day / 12 hours night, room temperature is 24 ° C, after feeding normal food for 7 days, the food is incorporated into the microcrystalline cellulose, and no microcrystalline fiber is added.
  • the fiber pentose sugar, the amount of arabinose in the food is 20, 40, 60, 80 g / kg of feed, the urine of the collected animal is analyzed for the arabinose content, the results are as follows: Feed containing microcrystalline cellulose containing microcrystalline cellulose containing microcrystalline cellulose containing microcrystalline cellulose containing microcrystalline cellulose containing labo sugar amount 0 amount 10% amount 20% amount 30% amount 40%
  • the sputum-type diabetic rats prepared with streptozotocin were 9 weeks old, the first group was the control group, 6 were fed with pure protein food, and metformin was used to control blood glucose; the second group of protein feed was used in Example 2 Fibrous pentose of microcrystalline cellulose, the arabinose content in the feed is 80 g/kg, and the content of microcrystalline cellulose in the fiber pentose product is 40%.
  • the blood is taken from the tail vein. After adding the anti-coagulant, the supernatant is obtained by centrifugation, and the pH of the blood is measured by a precision pH meter. The results are as follows:
  • the lyophilized fiber pentose solid product (ie, fiber pentose I) 800 g was added to 3 liters of 95% edible ethanol, then heated to reflux, and slowly added to about 100 ml. After pure water, reflux for about 10 minutes, slowly cool to 20 ° C, add a small amount of xylose seed crystals, and then store at this temperature for 24 hours, occasionally gently shaking. After 24 hours, the mixture was cooled to 0 ° C, and placed for 48 hours, filtered, and dried under vacuum to obtain 500 g of pure xylose with a purity of 98.6%.
  • the sputum-type diabetic rats prepared with streptozotocin were 9 weeks old, the first group was the control group, 6 were fed with pure protein food, and metformin was used to control blood glucose; the second group of protein feed was prepared using the pure wood prepared above.
  • Sugar the xylose content in the feed is 120 g / kg, does not contain additional microcrystalline cellulose, after three months of feeding, determination (take blood from the tail vein, add anti-coagulant, centrifuge to obtain clear liquid, precision pH meter determination)
  • the pH of their blood the results are as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Fiber pentose or a composition containing fiber pentose is used in the manufacture of foods or medicines for preventing and/or treating acidification of the body in diabetic patients. The composition comprises fiber pentose and substances that promote absorption in the body of fiber pentose. The substances that promote absorption of fiber pentose are selected from cellulose, vitamin B1, vitamin B5, vitamin B6, thyroxine, adrenalin, potassium ion, magnesium ion and sodium ion. The fiber pentose is xylose, ribose, arabinose, lyxose, ribulose and/or xylulose. The fiber pentose is prepared by mixing cellulose-containing biomass, water and catalyst, hydrolyzing and then fermenting with yeast. The catalyst is selected from hemicellulose hydrolase, organic acid, inorganic acid or biomimetic catalyst.

Description

纤维戊糖或含有纤维戊糖的组合物在制备预防和 /或治疗 糖尿病患者机体酸化的食品或药物中的用途 技术领域  Use of a fiber pentose or a fiber pentose-containing composition for the preparation of a food or a medicament for preventing and/or treating acidification of a body of a diabetic patient
本发明涉及纤维素生物质领域, 尤其涉及一种防治糖尿病患者机体酸化 的组合物。 背景技术  The present invention relates to the field of cellulosic biomass, and more particularly to a composition for controlling acidification of a body of a diabetic patient. Background technique
糖尿病是机体无法分泌胰岛素、 或者分泌胰岛素的数量或 /和胰岛素的 质量不足、 而造成身体无法有效降解代谢葡萄糖的一种疾病。 当前, 糖尿病 患者一般采用多食用蛋白质等来为身体提供必须的能量供应。 由于蛋白质等 物质的代谢不是身体最适宜的能量供应方式, 大量的这种代谢造成代谢的不 彻底, 并且由于大多数蛋白质分子中含有很多杂原子、 如氮、 硫、 和磷、 等 等, 长期累积的结果就是身体的酸化。  Diabetes is a disease in which the body cannot secrete insulin, or the amount of insulin secreted or/and the quality of insulin is insufficient, causing the body to be unable to effectively degrade metabolic glucose. Currently, people with diabetes generally use more protein and so on to provide the body with the necessary energy supply. Since the metabolism of substances such as proteins is not the most suitable way to supply energy to the body, a large amount of this metabolism causes incomplete metabolism, and since most protein molecules contain many heteroatoms such as nitrogen, sulfur, and phosphorus, etc., The cumulative result is the acidification of the body.
机体酸化是疾病患者和老年人普遍存在的现象, 健康者和青少年的机体 全部是微碱性的。 在酸性环境中, 许多高活性粒子如自由基的产生更容易, 使机体的氧化应激水平升高, 而氧化应激水平异常是机体内各种细胞损伤和 死亡的最根本原因, 非正常水平的氧化应激被认为是造成糖尿病和糖尿病慢 性并发症, 肺纤维化、 癫痫、 高血压、 动脉粥样硬化和相应的心血管疾病、 癌症、 肾病变、 和帕金森病等疾病的重要原因。 根据临床测评结果发现, 很 多患者如癌症患者, 基本上都是酸性体质, 维持机体处于微碱性状态, 是降 低氧化应激水平的重要手段之一。  Acidification of the body is a common phenomenon in patients with diseases and the elderly. The bodies of healthy people and adolescents are all slightly alkaline. In an acidic environment, many high-activity particles such as free radicals are more easily produced, which raises the body's oxidative stress level, and abnormal oxidative stress is the most fundamental cause of various cell damage and death in the body, abnormal levels. Oxidative stress is thought to be an important cause of chronic complications of diabetes and diabetes, pulmonary fibrosis, epilepsy, hypertension, atherosclerosis and corresponding cardiovascular diseases, cancer, nephropathy, and Parkinson's disease. According to the clinical evaluation results, many patients, such as cancer patients, are basically acidic, maintaining the body in a slightly alkaline state, which is one of the important means to reduce the level of oxidative stress.
食品的酸碱性, 并非以口感确定, 而是由食品在体内消化吸收代谢后所 产生的结果来确定的。 如果食品代谢后所产生的磷酸根、 硫酸根、 硝酸根、 氯离子等阴离子比较多, 就会造成机体酸化, 是酸性食品; 如果食品代谢后 所产生的钠离子、 钾离子、 镁离子、 钙离子等离子较多, 就易于造成机体碱 化, 是碱性食品。 柠檬酸等虽然口感酸性, 但是人体新陈代谢将其转化为水 和二氧化碳, 它属于中性食品; 蛋白质没有酸碱口味, 但是人体将其代谢后 会产生硫酸根、 硝酸根、 氯离子等阴离子, 它们属于酸性食品; 而糖类物质 的最终代谢产物都是水和二氧化碳。 由此可见, 当糖尿病患者发病后, 其食 品的主体从碳水化合物转为蛋白质后, 其身体极易发生酸化, 导致氧化应激 水平进一步升高。  The acidity and alkalinity of foods are not determined by mouthfeel, but by the results of digestion and absorption of food in the body. If there are more anions such as phosphate, sulfate, nitrate, and chloride ions produced after food metabolism, it will cause acidification of the body and be an acidic food. If the food is metabolized, sodium ions, potassium ions, magnesium ions, and calcium are produced. If there are many ionic plasmas, it is easy to cause alkalization of the body and it is an alkaline food. Although citric acid and so on are acidic, human metabolism converts it into water and carbon dioxide. It is a neutral food. Protein has no acid-base taste, but the body metabolizes it to produce anions such as sulfate, nitrate and chloride. It is an acidic food; the final metabolites of carbohydrates are water and carbon dioxide. It can be seen that when a diabetic patient becomes a subject, the body of the food is converted from carbohydrate to protein, and the body is highly susceptible to acidification, resulting in a further increase in oxidative stress.
天然五碳糖的代谢不需要胰岛素的参与, 并且它们的甜度类似于葡萄 糖, 所以天然的五碳糖是非常理想的葡萄糖替代糖类、 为糖尿病患者提供糖 源能量的物质和恢复糖尿病患者的饮食习惯如可以吃糖。 但是, 由于两个原 因限制了它们在生活中的使用。 一是五碳糖在身体内被吸收的程度偏低, 二 是它们的生产成本太高而造成绝大多数人不可能消费。 The metabolism of natural five-carbon sugars does not require the participation of insulin, and their sweetness is similar to that of glucose. Therefore, natural five-carbon sugar is an ideal glucose replacement sugar, a substance that provides sugar source energy for diabetic patients and restores diabetes. Eating habits can eat sugar. However, their use in life is limited for two reasons. First, the degree of absorption of five carbon sugars in the body is low, It is because their production costs are too high and most people are unlikely to consume.
因此, 本领域迫切需要提供一种含有天然五碳糖的物质, 它在体内吸收 程度高, 可有效防治糖尿病患者机体酸化, 而且生产成本低。 发明内容  Therefore, there is an urgent need in the art to provide a substance containing natural five-carbon sugar, which has a high degree of absorption in the body, can effectively prevent acidification of a body of a diabetic patient, and has low production cost. Summary of the invention
本发明旨在提供一种纤维戊糖或含有纤维戊糖的组合物的用途。  The present invention is directed to the use of a fiber pentose or a composition comprising a fiber pentose.
本发明的另一个目的是提供一种从纤维素生物质制备纯木糖的方法。 在本发明的第一方面, 提供了一种纤维戊糖或含有纤维戊糖的组合物的 用途, 用于制备预防和 /或治疗糖尿病患者机体酸化的食品或药物。  Another object of the present invention is to provide a process for preparing pure xylose from cellulosic biomass. In a first aspect of the invention, there is provided a use of a pentose pentose or a pentose-containing composition for the preparation of a food or medicament for preventing and/or treating acidification of a body of a diabetic patient.
在另一优选例中, 所述的含有纤维戊糖的组合物由纤维戊糖和促进纤维 戊糖在体内吸收的物质组成。  In another preferred embodiment, the fiber pentose-containing composition is composed of a fiber pentose sugar and a substance which promotes absorption of the fiber pentose sugar in the body.
在另一优选例中, 以 100重量份组合物计, 它含有:  In another preferred embodiment, based on 100 parts by weight of the composition, it contains:
1 100重量份纤维戊糖; 和  1 100 parts by weight of pentose sugar; and
0-99 重量份糖吸收促进剂; 所述的糖吸收促进剂选自下述的一种或多 种物质: 纤维素、 维生素 Bl、 维生素 B5、 维生素 B6、 甲状腺素、 肾上腺素、 钾离子、 镁离子、 钠离子。  0-99 parts by weight of a sugar absorption enhancer; the sugar absorption enhancer is selected from one or more of the following: cellulose, vitamin B1, vitamin B5, vitamin B6, thyroxine, adrenaline, potassium ion, Magnesium ions, sodium ions.
在另一优选例中, 以 100重量份组合物计, 它含有: 1 100重量份纤维 戊糖; 和 0.001— 99重量份糖吸收促进剂。  In another preferred embodiment, it contains: 100 parts by weight of pentose sugar; and 0.001 - 99 parts by weight of a sugar absorption enhancer, based on 100 parts by weight of the composition.
在另一优选例中, 所述纤维戊糖和糖吸收促进剂的重量比为 0.001— In another preferred embodiment, the weight ratio of the pentose sugar to the sugar absorption enhancer is 0.001.
1000:1, 较佳地为 0.015— 10:1, 更佳地为 0.02— 0.7:1。 1000:1, preferably 0.015 - 10:1, more preferably 0.02 - 0.7:1.
在另一优选例中, 所述的促进纤维戊糖在体内吸收的物质包括所有的可 以促进纤维戊糖在体内吸收的物质, 既可以是大分子物质、 也可以是小分子 物质、 甚至于离子, 包括但不限于纤维素、 维生素 Bl、 维生素 B5、 维生素 B6、 甲状腺素、 肾上腺素、 钾离子、 镁离子、 钠离子、 等等。  In another preferred embodiment, the substance for promoting absorption of the fiber pentose in the body includes all substances which promote the absorption of the fiber pentose in the body, and may be a macromolecular substance, a small molecule substance or even an ion. , including but not limited to cellulose, vitamin B1, vitamin B5, vitamin B6, thyroxine, adrenaline, potassium, magnesium, sodium, and the like.
在另一优选例中, 所述的纤维素包括所有的纤维素, 优选微晶纤维素, 最优选纳米级的纤维素。  In another preferred embodiment, the cellulose comprises all of the cellulose, preferably microcrystalline cellulose, most preferably nano-sized cellulose.
在另一优选例中, 所述的纤维戊糖选自下述的一种或多种: 木糖 (xylose)、 核糖(ribose)、 阿拉伯糖(arabinose)、 来苏糖(lyxose)、 核酮 糖(ribulose)、 木酮糖(xylulose)。  In another preferred embodiment, the fiber pentose sugar is selected from one or more of the following: xylose, ribose, arabinose, lyxose, nucleoside Ribulose, xylulose.
在另一优选例中, 所述的纤维戊糖通过以下步骤得到:  In another preferred embodiment, the fiber pentose is obtained by the following steps:
(a)将含有纤维素的生物质和水混合, 在 20— 18CTC水解得到液体混合 物 I; 和  (a) mixing the biomass containing cellulose with water and hydrolyzing at 20-18 CTC to obtain liquid mixture I;
(b) 将液体混合物 I和酒精酵母在 20— 60°C混合 6 48小时后, 滤去 固体物, 浓缩得到纤维戊糖。 在另一优选例中, 所述的纤维戊糖通过以下步骤得到: (b) After mixing the liquid mixture I and the alcohol yeast at 20 to 60 ° C for 6 to 48 hours, the solid matter was filtered off and concentrated to obtain a fiber pentose. In another preferred embodiment, the fiber pentose is obtained by the following steps:
(1) 将含有纤维素的生物质、 水和催化剂在 30— 18CTC混合 3— 600分 钟, 水解得到液体混合物 I; 所述的催化剂选自: 半纤维素水解酶、 有机酸、 无机酸、 或仿生催化剂; 所述的有机酸选自: 含 20 个碳以下的有机酸; 所 述的无机酸选自: 硫酸、 盐酸、 磷酸; 所述的仿生催化剂选自 [CpFeCO (马来 酸)] BF4、 或乙二氨二乙酸铁络合物;  (1) The cellulose-containing biomass, water and catalyst are mixed at 30-18 CTC for 3 to 600 minutes, and hydrolyzed to obtain a liquid mixture I; the catalyst is selected from the group consisting of: hemicellulose hydrolase, organic acid, inorganic acid, or a biomimetic catalyst; the organic acid is selected from the group consisting of: an organic acid containing less than 20 carbons; the inorganic acid is selected from the group consisting of: sulfuric acid, hydrochloric acid, and phosphoric acid; and the biomimetic catalyst is selected from the group consisting of [CpFeCO (maleic acid)] BF4 Or iron bis(diamine diacetate) complex;
(2) 将液体混合物 I和酒精酵母在 20— 60°C混合 6— 48小时, 得到液 体混合物 Π; 和  (2) mixing liquid mixture I and alcohol yeast at 20-60 ° C for 6 to 48 hours to obtain a liquid mixture Π;
(3) 液体混合物 II经过离子交换, 得到纤维戊糖。  (3) The liquid mixture II is ion-exchanged to obtain a fiber pentose.
在另一优选例中, 所述的纤维戊糖以纤维戊糖总重量计, 含有阿拉伯糖 l-90wt%; 优选所述的纤维戊糖中含有阿拉伯糖 5— 25wt%。 In another preferred embodiment, the fiber pentose contains 1 to 90% by weight of arabinose, based on the total weight of the fiber pentose ; preferably, the fiber pentose contains 5-25% by weight of the arabinose.
在另一优选例中, 所述的纤维戊糖通过以下步骤得到:  In another preferred embodiment, the fiber pentose is obtained by the following steps:
(a)将含有纤维素的生物质和水混合, 在 90— 18CTC水解得到液体混合 物 I; 和  (a) mixing the cellulose-containing biomass with water and hydrolyzing at 90-18 CTC to obtain liquid mixture I;
(b)将液体混合物 I和酒精酵母在 20— 40°C混合 12— 48小时, 得到纤 维戊糖。  (b) Mixing the liquid mixture I and the alcohol yeast at 20-40 ° C for 12 to 48 hours to obtain a cellulose pentose.
在另一优选例中, 所述的纤维戊糖通过以下步骤得到:  In another preferred embodiment, the fiber pentose is obtained by the following steps:
(1)将含有纤维素的生物质、 水和催化剂在 90— 18CTC混合 30— 120分 钟, 水解得到液体混合物 I; 所述的催化剂选自: 半纤维素水解酶、 有机酸、 无机酸、 或仿生催化剂; 所述的有机酸选自: 含 20 个碳以下的有机酸; 所 述的无机酸选自: 硫酸、 盐酸、 磷酸; 所述的仿生催化剂选自: [CpFeCO (马 来酸)] BF4、 或乙二氨二乙酸铁络合物;  (1) The cellulose-containing biomass, water and catalyst are mixed at 90-18 CTC for 30-120 minutes, and hydrolyzed to obtain a liquid mixture I; the catalyst is selected from the group consisting of: hemicellulose hydrolase, organic acid, inorganic acid, or a biomimetic catalyst; the organic acid is selected from the group consisting of: an organic acid containing less than 20 carbons; the inorganic acid is selected from the group consisting of: sulfuric acid, hydrochloric acid, and phosphoric acid; and the biomimetic catalyst is selected from the group consisting of: [CpFeCO (maleic acid)] BF4, or iron diammonium diacetate complex;
(2)将液体混合物 I和酒精酵母在 20— 40°C混合 12— 48小时, 得到液 体混合物 Π; 和  (2) mixing liquid mixture I and alcohol yeast at 20-40 ° C for 12 to 48 hours to obtain a liquid mixture Π;
(3) 液体混合物 II经过离子交换, 得到纤维戊糖。  (3) The liquid mixture II is ion-exchanged to obtain a fiber pentose.
在另一优选例中, 所述的食品包括固体食品和液体食品。 在本发明的第二方面, 提供了一种从纤维素生物质制备纯木糖的方法, 所述的方法包括步骤: 将纤维戊糖经过简单的乙醇 /水混合溶剂重结晶; 所述的纤维戊糖通过以下步骤得到:  In another preferred embodiment, the food product comprises a solid food and a liquid food. In a second aspect of the invention, there is provided a method of preparing pure xylose from cellulosic biomass, the method comprising the steps of: recrystallizing a fiber pentose sugar through a simple ethanol/water mixed solvent; Pentose is obtained by the following steps:
(1)将含有纤维素的生物质、 水和催化剂在 90— 18CTC混合 30— 120分 钟, 水解得到液体混合物 I; 所述的催化剂选自: 半纤维素水解酶、 有机酸、 无机酸、 或仿生催化剂; 所述的有机酸选自: 含 20 个碳以下的有机酸; 所 述的无机酸选自: 硫酸、 盐酸、 磷酸; 所述的仿生催化剂选自: [CpFeCO (马 来酸)] BF4、 或乙二氨二乙酸铁络合物; ( 2 )将液体混合物 I和酒精酵母在 20— 40 °C混合 12— 48小时, 得到液 体混合物 Π ; 和 (1) The cellulose-containing biomass, water and catalyst are mixed at 90-18 CTC for 30-120 minutes, and hydrolyzed to obtain a liquid mixture I; the catalyst is selected from the group consisting of: hemicellulose hydrolase, organic acid, inorganic acid, or a biomimetic catalyst; the organic acid is selected from the group consisting of: an organic acid containing less than 20 carbons; the inorganic acid is selected from the group consisting of: sulfuric acid, hydrochloric acid, and phosphoric acid; and the biomimetic catalyst is selected from the group consisting of: [CpFeCO (maleic acid)] BF4, or iron diammonium diacetate complex; (2) mixing the liquid mixture I and the alcohol yeast at 20-40 ° C for 12 to 48 hours to obtain a liquid mixture Π;
( 3 ) 液体混合物 I I经过离子交换, 得到纤维戊糖。 据此,本发明提供了一种含有天然五碳糖的物质, 它在体内吸收程度高, 可有效防治糖尿病患者机体酸化, 而且生产成本低。 具体实施方式  (3) The liquid mixture I I is ion-exchanged to obtain a fiber pentose. Accordingly, the present invention provides a substance containing natural five-carbon sugar, which has a high degree of absorption in the body, can effectively prevent acidification of a body of a diabetic patient, and has low production cost. detailed description
发明人经过广泛而深入的研究, 发现通过将含有纤维素的生物质精炼, 可以得到天然五碳糖的产品: 纤维戊糖, 当其同一些物质混合后, 可以大大 提高天然五碳糖在体内的有效吸收, 从而可以为糖尿病患者提供糖源能量的 产品, 防止糖尿病患者因长期主要使用蛋白质为能量物质而造成机体的酸 化, 进而具有降低氧化应激、 预防疾病的功能。 定义  After extensive and in-depth research, the inventors found that by refining cellulose-containing biomass, a product of natural five-carbon sugar can be obtained: Fiber pentose, when mixed with other substances, can greatly enhance natural five-carbon sugar in the body. The effective absorption can provide a source of sugar energy for diabetic patients, preventing the acidification of the body caused by long-term use of protein as an energy substance in diabetic patients, thereby reducing oxidative stress and preventing diseases. Definition
如本文所用, "含纤维素的生物质" 和 "含有纤维素的生物质" 可以互 换使用, 都是指所有含有纤维素的物质, 其范围包括传统定义中的纤维素生 物质, 包括植物的种子、 果实、 茎、 叶、 和根, 甚至包括一些微生物。 所述 植物包括所有的无毒的植物、 产品的特性不受植物来源的影响。 所有的含有 纤维素的生物质均可以使用, 优选半纤维素的含量以纤维素生物质总重量计 为 5wt%以上的物质, 最优选半纤维素的含量以纤维素生物质总重量计为 10wt%以上的物质。  As used herein, "cellulose-containing biomass" and "cellulose-containing biomass" are used interchangeably and refer to all cellulose-containing materials, including cellulose biomass in the traditional definition, including plants. The seeds, fruits, stems, leaves, and roots even include some microorganisms. The plants include all non-toxic plants, and the properties of the product are not affected by the source of the plant. All cellulose-containing biomass may be used, preferably a hemicellulose content of 5% by weight or more based on the total weight of the cellulosic biomass, most preferably a hemicellulose content of 10 wt% based on the total weight of the cellulosic biomass. More than % of the substance.
如本文所用, "纤维素生物质" 是指以纤维素、 半纤维素、 和木质素为 主要成分的生物质, 一般不包括植物的果实。  As used herein, "cellulosic biomass" refers to biomass containing cellulose, hemicellulose, and lignin as a major component, and generally does not include the fruits of plants.
微晶纤维素是一种纯净的天然纤维素解聚产物, 呈微细粉末状, 白色, 无气味, 无味道; 由能自由流动的结晶粉末 (非纤维状的微粒子) 组成。 不 溶于水、 稀释的酸和多数的有机溶剂, 微溶于 20%的碱溶液。 可直接用于干 粉压片, 广泛用作药物赋形剂、 流动性助剂、 填充物、 崩解剂、 抗粘剂、 吸 附剂、 胶囊稀释剂等。 纳米微晶纤维素在本发明中是指横截面长度为 10-20 纳米, 纤维长度为小于 100纳米的纤维素物质。  Microcrystalline cellulose is a pure natural cellulose depolymerization product, which is in the form of fine powder, white, odorless, tasteless; composed of free-flowing crystalline powder (non-fibrous particles). Insoluble in water, diluted acid and most organic solvents, slightly soluble in 20% alkali solution. It can be directly used for dry powder tableting, and is widely used as a pharmaceutical excipient, a flow aid, a filler, a disintegrant, an anti-adhesive agent, an adsorbent, a capsule diluent, and the like. Nanocrystalline cellulose in the present invention refers to a cellulosic material having a cross-sectional length of 10 to 20 nm and a fiber length of less than 100 nm.
如本文所用, 纤维戊糖选自所有的天然五碳糖, 如五碳醛糖的木糖 (xylose)、 核糖(ribose)、 阿拉伯糖(arab inose)、 来苏糖(lyxose) , 五碳 酮糖的核酮糖(r ibulose)、 木酮糖(xylulose)、 等。 纤维戊糖既可以是单一 的纯五碳糖, 也可以是它们的混合物, 各糖在混合物中的含量不限。 在本发 明中, "纤维戊糖" 、 "天然五碳糖组合物" 或 "天然五碳糖" 可以互换使 用, 都是指所有自然界中天然生成的含五个碳原子的单糖、 或者是它们简单 的衍生物或多聚物。 As used herein, the fiber pentose sugar is selected from all natural five carbon sugars, such as xylose, ribose, arab inose, lyxose, and pentoketone. Sugar ribulose (r ibulose), xylulose, xylulose, and the like. The pentose sugar may be either a single pure five-carbon sugar or a mixture thereof, and the content of each sugar in the mixture is not limited. In the present invention, "fibrous pentose", "natural five-carbon sugar composition" or "natural five-carbon sugar" can be interchanged. Use, all refer to all naturally occurring monosaccharides containing five carbon atoms in nature, or simply derivatives or polymers thereof.
Figure imgf000006_0001
如本文所用, "仿生催化剂" 是指至少含有一个催化区域 (catalytic domain ) 、 禾口一个纤维素结合区域(cel lulose binding domain)的人工合成 的催化剂, 如 [CpFeCO (马来酸)] BF4、 乙二氨二乙酸铁络合物、 等等。 专利 申请 PCT/CN/2007/071114 中对仿生催化剂有详尽的描述, 其中所揭示的仿 生催化剂全部可以用于此处的产品制备。 另一方面, 本发明所述的纤维戊糖可以通过下述步骤获得:
Figure imgf000006_0001
As used herein, "mimetic catalyst" refers to a synthetic catalyst containing at least one catalytic domain and a cel lulose binding domain, such as [CpFeCO (maleic acid)] BF4, Iron complex of ethylene diamine diacetate, and the like. The biomimetic catalyst is described in detail in the patent application PCT/CN/2007/071114, the entire disclosure of which is incorporated herein by reference. In another aspect, the pentose sugar of the present invention can be obtained by the following steps:
( a )将含有纤维素的生物质和水混合, 在 20— 18CTC水解得到液体混合 物 I; 和  (a) mixing the cellulose-containing biomass with water and hydrolyzing at 20-18 CTC to obtain liquid mixture I;
( b ) 将液体混合物 I和酒精酵母在 20— 60°C混合 6— 48小时, 滤去固 体物, 浓缩得到纤维戊糖。  (b) The liquid mixture I and the alcohol yeast are mixed at 20 to 60 ° C for 6 to 48 hours, the solid matter is filtered off, and concentrated to obtain a fiber pentose.
在本发明的一个较佳实施例中, 通过以下步骤得到纤维戊糖:  In a preferred embodiment of the invention, the fiber pentose is obtained by the following steps:
第一步, 将粉碎的含有纤维素的生物质使用近沸的水 (80— 98 °C, 较佳 地为 90— 95 °C ) 脱蜡;  In the first step, the pulverized cellulose-containing biomass is dewaxed using near-boiling water (80-98 ° C, preferably 90-95 ° C);
第二步, 将脱蜡后的含有纤维素的生物质和催化剂在 30— 14CTC混合 3 - 600 分钟, 水解、 固液分离, 得到液体混合物 I; 所述的催化剂选自: 半 纤维素水解酶、 有机酸、 无机酸、 或仿生催化剂; 所述的有机酸选自: 含 20 个碳以下的有机酸; 所述的无机酸选自: 硫酸、 盐酸、 磷酸; 所述的仿生催 化剂选自: 专利申请 PCT/CN/2007/071114所揭示的;  In the second step, the dewaxed cellulose-containing biomass and catalyst are mixed at 30-14 CTC for 3 - 600 minutes, hydrolyzed, and solid-liquid separated to obtain a liquid mixture I; the catalyst is selected from the group consisting of: hemicellulose hydrolase The organic acid, the inorganic acid, or the biomimetic catalyst; the organic acid is selected from the group consisting of: an organic acid containing less than 20 carbons; the inorganic acid is selected from the group consisting of: sulfuric acid, hydrochloric acid, and phosphoric acid; and the biomimetic catalyst is selected from the group consisting of: Patent application PCT/CN/2007/071114;
第三步, 分离或灭活催化剂; 所述的分离包括将液体混合物 I通过大孔 吸附树脂; 所述的灭活包括加热、 中和、 等等;  In the third step, the catalyst is separated or inactivated; the separation comprises passing the liquid mixture I through the macroporous adsorption resin; the inactivation comprises heating, neutralization, etc.;
第四步, 将液体混合物 I和酒精酵母在 20— 60°C混合 6— 48小时, 滤去 固体, 得到液体产物 Π ;  In the fourth step, the liquid mixture I and the alcohol yeast are mixed at 20-60 ° C for 6 to 48 hours, and the solid is filtered to obtain a liquid product Π;
第五步, 将液体产物 I I经过离子交换, 得到纤维戊糖液。  In the fifth step, the liquid product I I is subjected to ion exchange to obtain a fiber pentose solution.
第五步中的离子交换包括阳离子交换、 和阴离子交换, 有时为了提高产 品的品质, 还加上一个同时含有阳离子树脂和阴离子树脂的混合柱。 洗脱一 般均是使用纯水, 交换树脂的再生一般都是氢氧化钠水溶液和稀盐酸。 本发明提供的防治糖尿病患者机体酸化的组合物中含有纤维戊糖和戊 糖吸收促进剂; 所述的糖吸收促进剂选自下述的一种或多种物质: 纤维素、 维生素 B l、 维生素 B5、 维生素 B6、 甲状腺素、 肾上腺素、 钾离子、 镁离子、 钠离子。 其中的纤维戊糖和糖吸收促进剂如微晶纤维素的重量比为 0. 001— 1000: 1 , 较佳地为 0. 015— 10: 1, 更佳地为 0. 02— 0. 7 : 1 The ion exchange in the fifth step includes cation exchange, and anion exchange, and sometimes in order to improve the quality of the product, a mixed column containing both a cationic resin and an anionic resin is added. Elution Generally, pure water is used, and the regeneration of the exchange resin is generally an aqueous solution of sodium hydroxide and dilute hydrochloric acid. The composition for preventing acidification of a body of a diabetic patient provided by the invention comprises a fiber pentose sugar and a pentose sugar absorption enhancer; wherein the sugar absorption enhancer is selected from one or more of the following substances: cellulose, vitamin B, Vitamin B5, vitamin B6, thyroxine, adrenaline, potassium ion, magnesium ion, sodium ion. 015 - 10: 1, more preferably 0. 02 - 0. 7, the weight ratio of the weight of the pentose saccharide and the sugar absorbing agent, such as the microcrystalline cellulose is 0. 001 - 1000: 1 , preferably 0. 015 - 10: 1, more preferably 0. 02 - 0. : 1
本发明提供的组合物可以通过将纤维戊糖和选自下述的一种或多种物 质混合得到: 纤维素、 维生素 B l、 维生素 B5、 维生素 B6、 甲状腺素、 肾上 腺素、 钾离子、 镁离子、 钠离子。 混合包括常规的混合、 共结晶、 共干燥、 所说的维生素、 甲状腺素、 肾上腺素、 钾离子、 镁离子、 钠离子等在组 合物中的含量是它们允许的最高安全含量。  The composition provided by the present invention can be obtained by mixing a fiber pentose with one or more substances selected from the group consisting of cellulose, vitamin B1, vitamin B5, vitamin B6, thyroxine, adrenaline, potassium ion, magnesium. Ions, sodium ions. Mixing, including conventional mixing, co-crystallization, co-drying, said vitamins, thyroxine, adrenaline, potassium ions, magnesium ions, sodium ions, etc., in the composition is the highest safe level they allow.
本发明中用于增强五碳糖吸收的物质包括纤维素、 维生素 B l、 维生素 B5、 维生素 B6、 甲状腺素、 肾上腺素、 钾离子、 镁离子、 钠离子、 等等。 所 说的纤维素在组合物中的含量为 1 %-99%之间。  The substance for enhancing the absorption of the five-carbon sugar in the present invention includes cellulose, vitamin B1, vitamin B5, vitamin B6, thyroxine, adrenaline, potassium ion, magnesium ion, sodium ion, and the like. The cellulose is present in the composition in an amount between 1% and 99%.
在本发明的另一个较佳实施例中, 提供了一种生产本发明组合物的方 法, 包括如下步骤:  In another preferred embodiment of the invention, a method of producing a composition of the invention is provided, comprising the steps of:
(a)粉碎的纤维素生物质使用近沸的热水脱蜡;  (a) the pulverized cellulosic biomass is dewaxed using near boiling hot water;
(b)脱蜡后的纤维素生物质用于水解制备纤维戊糖产品, 水解一般在纯 水中进行, 水解催化剂一般为半纤维素水解酶、 有机酸、 无机酸、 和仿生催 化剂;  (b) Dewaxed cellulosic biomass is used for the hydrolysis to prepare a fiber pentose product, and the hydrolysis is generally carried out in pure water. The hydrolysis catalyst is generally a hemicellulose hydrolase, an organic acid, a mineral acid, and a biomimetic catalyst;
( c ) 固液分离得到含纤维戊糖的溶液, 分离或灭活催化剂;  (c) solid-liquid separation to obtain a solution containing cellulose pentose, separating or inactivating the catalyst;
( d ) 发酵法除去所含的六碳糖;  (d) removing the contained six carbon sugars by fermentation;
( e ) 固液分离后得液体产品;  (e) obtaining a liquid product after solid-liquid separation;
( f ) 和需要量的糖吸收促进剂混合均匀得到需要的产品。 用途  (f) Mix with the required amount of sugar absorption enhancer to obtain the desired product. Use
本发明提供的纤维戊糖或含有纤维戊糖的组合物可用于制备预防和 /或 治疗糖尿病患者机体酸化的产品, 既可以是一般食品、 保健食品、 或者药物。  The fiber pentose or the fiber pentose-containing composition provided by the present invention can be used for the preparation of a product for preventing and/or treating the acidification of a body of a diabetic patient, which can be a general food, a health food, or a medicine.
本发明提供的纤维戊糖或含有纤维戊糖的组合物还可以用于制备促进 纤维戊糖吸收的药物, 尤其可用于制备促进阿拉伯糖吸收的药物。  The fiber pentose or the fiber pentose-containing composition provided by the present invention can also be used for the preparation of a drug for promoting the absorption of pentose sugar, and particularly for the preparation of a drug for promoting the absorption of arabinose.
所述的药物可以通过将本发明提供的纤维戊糖或含有纤维戊糖的组合 物和药学上可接受的载体混合得到。  The drug can be obtained by mixing the fiber pentose or the fiber pentose-containing composition provided by the present invention with a pharmaceutically acceptable carrier.
如本文所用, 术语 "药学上可接受的载体" 指用于治疗剂给药的载体, 包括各种赋形剂和稀释剂。 该术语指这样一些药剂载体: 它们本身并不是必 要的活性成分, 且施用后没有过分的毒性。 合适的载体是本领域普通技术人 员所熟知的。 在 Remi ngton' s Pharmac eut i cal Sc i enc e s (Mack Pub. Co., N. J. 1991 )中可找到关于药学上可接受的赋形剂的充分讨论。 在组合物中药 学上可接受的载体可包括液体, 如水、 盐水、 甘油和乙醇。 另外, 这些载体 中还可能存在辅助性的物质, 如崩解剂、 润湿剂、 乳化剂、 pH缓冲物质等。 The term "pharmaceutically acceptable carrier" as used herein refers to a carrier for the administration of a therapeutic agent, Various excipients and diluents are included. The term refers to pharmaceutical carriers which are not themselves essential active ingredients and which are not excessively toxic after administration. Suitable carriers are well known to those of ordinary skill in the art. A full discussion of pharmaceutically acceptable excipients can be found in Remi ngton's Pharmac eut i cal Sc i enc es (Mack Pub. Co., NJ 1991). Pharmaceutically acceptable carriers in the compositions may include liquids such as water, saline, glycerol and ethanol. In addition, auxiliary substances such as disintegrants, wetting agents, emulsifiers, pH buffering substances and the like may also be present in these carriers.
所述药物可以根据不同给药途径而制备成各种剂型, 如固体制剂, 或液 体制剂。 这些剂型以下面方式之一施用: 口服、 喷雾吸入、 直肠用药、 鼻腔 用药、 颊部用药、 局部用药、 非肠道用药, 如皮下、 静脉、 肌肉、 腹膜内、 鞘内、 心室内、 胸骨内和颅内注射或输入, 或借助一种外植储器用药。 本发明提供了一种防止糖尿病患者身体酸化的产品, 具体的讲, 是提供 一种天然五碳糖的单体或者它们之间的组合物, 同时, 还提供一种能够促进 五碳糖被身体吸收的方法, 使得糖尿病患者仍然可以使用糖源能量, 协助防 止糖尿病患者的机体酸化, 降低氧化应激水平, 预防糖尿病慢性并发症。 天然五碳糖基本上存在于所有的含有纤维素的生物质中, 包括纤维素生 物质中, 包括它们的种子、 果实、 茎、 叶、 根、 等等。 这类纤维戊糖的多聚 物在食物的制作过程中较易水解为单糖, 它们在体内的代谢不需要胰岛素的 参与, 可以剌激身体其它功能的健全和发展, 同时又可以减轻胰岛的工作压 力, 对维持人体的健康非常重要。 但是, 由于所谓的技术进步, 人类食品中 精加工的比重越来越大, 这些天然五碳糖的摄入大幅减少。 虽然人类又在设 法补充, 如制备水果醋等产品以期增加身体天然五碳糖的摄入, 但是, 由于 人类饮食习惯的影响, 使用这类产品的人口很少。 所以, 本发明中所提供这 种天然五碳糖组合物, 对一般的消费者来说, 也具备重大意义。 由于天然的阿拉伯糖在迄今为止的研究成果中显示都是吸收最差的五 碳糖, 本发明以天然的阿拉伯糖为例来说明。 应理解, 以天然的阿拉伯糖为 例仅是用于更好的说明本发明, 而不是限制本发明的范围。 本发明提到的上述特征, 或实施例提到的特征可以任意组合。 本案说明 书所揭示的所有特征可与任何组合物形式并用, 说明书中所揭示的各个特 征, 可以任何可提供相同、 均等或相似目的的替代性特征取代。 因此除有特 别说明, 所揭示的特征仅为均等或相似特征的一般性例子。 本发明的主要优点在于: The medicament may be prepared into various dosage forms, such as a solid preparation, or a liquid preparation, depending on the administration route. These dosage forms are administered in one of the following ways: oral, spray inhalation, rectal administration, nasal administration, buccal administration, topical administration, parenteral administration, such as subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal And intracranial injection or input, or with an explant reservoir. The present invention provides a product for preventing acidification of a body of a diabetic patient, and more particularly to provide a natural five-carbon sugar monomer or a composition therebetween, and at the same time, to provide a body capable of promoting five-carbon sugar by the body. The method of absorption allows diabetic patients to still use the energy of sugar source, help prevent acidification of the body of diabetic patients, reduce the level of oxidative stress, and prevent chronic complications of diabetes. Natural five-carbon sugars are found in virtually all cellulose-containing biomass, including cellulosic biomass, including their seeds, fruits, stems, leaves, roots, and the like. These polymers of pentose sugars are more easily hydrolyzed into monosaccharides during the production of food. Their metabolism in the body does not require the participation of insulin, which can stimulate the health and development of other functions of the body, while at the same time reducing the islets of the islets. Work stress is very important to maintain the health of the human body. However, due to so-called technological advances, the proportion of finishing in human food is increasing, and the intake of these natural five-carbon sugars is greatly reduced. Although humans are trying to supplement, such as the preparation of fruit vinegar and other products in order to increase the body's natural five-carbon sugar intake, but due to the influence of human diet, the population of such products is very small. Therefore, the natural five-carbon sugar composition provided in the present invention is also of great significance to the average consumer. Since natural arabinose has been shown to be the worst-absorbing five-carbon sugar in the research results to date, the present invention is exemplified by natural arabinose. It is to be understood that natural arabinose is used as an example to better illustrate the invention and is not intended to limit the scope of the invention. The above-mentioned features mentioned in the present invention, or the features mentioned in the embodiments, may be arbitrarily combined. All of the features disclosed in the present specification can be used in combination with any of the compositions, and the various features disclosed in the specification can be substituted for any alternative feature that provides the same, equal or similar purpose. Therefore, unless otherwise stated, the disclosed features are only a general example of equivalent or similar features. The main advantages of the invention are:
1、 本发明提供的产物有效降低糖尿病患者机体的酸化;  1. The product provided by the invention effectively reduces the acidification of the body of a diabetic patient;
2、 本发明提供的产物可以恢复糖尿病患者的正常生活习惯;  2. The product provided by the invention can restore the normal living habits of diabetic patients;
3、 本发明提供的组合物可有效促进五碳糖在体内的吸收;  3. The composition provided by the invention can effectively promote the absorption of five carbon sugars in the body;
4、 本发明获得天然五碳糖的成本低廉。 下面结合具体实施例, 进一步阐述本发明。 应理解, 这些实施例仅用于 说明本发明而不用于限制本发明的范围。 下列实施例中未注明具体条件的实 验方法, 通常按照常规条件或按照制造厂商所建议的条件。 除非另外说明, 否则所有的百分数、 比率、 比例、 或份数按重量计。  4. The invention achieves low cost of obtaining natural five-carbon sugar. The invention is further illustrated below in conjunction with specific embodiments. It is to be understood that the examples are not intended to limit the scope of the invention. The experimental methods in which the specific conditions are not indicated in the following examples are usually carried out according to conventional conditions or according to the conditions recommended by the manufacturer. All percentages, ratios, ratios, or parts are by weight unless otherwise indicated.
本发明中的重量体积百分比中的单位是本领域技术人员所熟知的, 例如 是指在 100毫升的溶液中溶质的重量。  The unit of weight percent by volume in the present invention is well known to those skilled in the art and, for example, refers to the weight of the solute in a 100 ml solution.
除非另行定义, 文中所使用的所有专业与科学用语与本领域熟练人员所 熟悉的意义相同。 此外, 任何与所记载内容相似或均等的方法及材料皆可应 用于本发明方法中。 文中所述的较佳实施方法与材料仅作示范之用。 实施例 1A  Unless otherwise defined, all professional and scientific terms used herein have the same meaning as those skilled in the art. In addition, any methods and materials similar or equivalent to those described can be used in the methods of the invention. The preferred embodiments and materials described herein are for illustrative purposes only. Example 1A
制备纤维戊糖 I  Preparation of fiber pentose I
1000克 (干重) 粉碎了的麦秸 (半纤维素含量为 21% ) 和接近沸点的热 水接触 (例如用热水冲洗) 10分钟后, 尽量将其压净水分后, 转移到 10升 的压力反应釜内, 然后加入 50mM的仿生催化剂 [CpFeCO (马来酸)] BF4 (专利 申请 PCT/CN/2007/071 1 14 ) , 搅拌下将混合物加热到近 l OOoC并维持在此温 度约 60分钟, 冷却到室温后, 固液分离得到液体产品。  1000 g (dry weight) The smashed wheat straw (half cellulose content is 21%) is contacted with hot water close to the boiling point (for example, washed with hot water). After 10 minutes, try to press it to moisture and transfer it to 10 liters. In a pressure reactor, then 50 mM of a biomimetic catalyst [CpFeCO (maleic acid)] BF4 (patent application PCT/CN/2007/071 1 14 ) was added, and the mixture was heated to near 100 °C with stirring and maintained at this temperature. After 60 minutes, after cooling to room temperature, solid-liquid separation gave a liquid product.
液体产品通过 3cmx60cm的 XAD-4大孔吸附树脂柱, 流速 2毫升 /分钟, 所得的纤维戊糖水溶液中基本上检测不到催化剂, 然后调 pH为 5. 5 后加入 约 1. 5%豆饼粉, 121 oC灭菌 30分钟后加入 1%高效安琪酿酒干酵母, 34 oC 下发酵 24 小时。 取样检测, 六碳糖基本检测不到, 加热将酵母灭活后, 过 滤进行固液分离, 得液体产品。  The 5% of the bean cake powder is added after the 5% of the bean cake powder is added to the 5% of the bean cake powder. After sterilization for 30 minutes at 121 oC, add 1% high-efficiency Anqi dry yeast and ferment for 24 hours at 34 °C. Sampling and testing, six carbon sugars are basically not detected, and the yeast is inactivated by heating, and the solid-liquid separation is carried out by filtration to obtain a liquid product.
液体产品过离子交换(732-阳离子交换树脂柱、 721 -阴离子交换树脂柱、 和混床离子交换柱) , 浓缩到含糖量 (总糖含量, 包括所有五碳糖, 使用阿 贝折光仪, 液相色谱精确定量) 约为 50%的水溶液, 其中阿拉伯糖的含量约 为 12%, 总共得到的液体产品为 260毫升, 该产品的 HPLC色谱只检测到阿拉 伯糖和木糖, 六碳糖没有观测到。 重复多次制备, 以得到足够的固体产品备 用。  Liquid products are ion exchanged (732-cation exchange resin column, 721 - anion exchange resin column, and mixed bed ion exchange column), concentrated to sugar content (total sugar content, including all five carbon sugars, using Abbe refractometer, Accurate quantification by liquid chromatography) Approximately 50% aqueous solution, wherein the arabinose content is about 12%, and the total liquid product obtained is 260 ml. The HPLC chromatogram of the product only detects arabinose and xylose, and the six carbon sugar does not. Observed. The preparation was repeated several times to obtain sufficient solid product preparation.
液相色谱法 HPLC为经典单糖分析方法, 使用 SUPELC0S IL 的 LC-NH2分 离柱 (250X4. 6mm ) , 流动相为乙腈: 水 =3 : 1, 流速为 1 毫升 /分钟, 折射 率检测器, 核糖的保留时间在 5. 8分钟左右、 木糖的保留时间在 6. 6分钟左 右、阿拉伯糖的保留时间在 7. 3分钟左右、果糖的保留时间在 8. 2分钟左右、 葡萄糖的保留时间在 9. 7分钟左右、 半乳糖的保留时间在 10. 2分钟左右。 Liquid Chromatography HPLC is a classical monosaccharide analysis method using LC-NH2 of SUPELC0S IL From the column (250X4. 6mm), the mobile phase is acetonitrile: water = 3: 1, the flow rate is 1 ml / min, the refractive index detector, the retention time of ribose is about 5.8 minutes, and the retention time of xylose is 6. 6分钟左右。 The retention time of the arabinose is about 7.3 minutes, the retention time of the fructose is about 8.2 minutes, the retention time of the glucose is about 7.9 minutes, and the retention time of the galactose is about 10. 2 minutes.
如果需要制备固体产品, 可采用冻干 (冻干法得固体产品 135克, 含水 量为 2% ) 或者喷雾干燥法制得; 如果需要制备液体产品, 则在惰性气体保护 下密封包装即可。 实施例 1B  If it is necessary to prepare a solid product, it can be obtained by lyophilization (135 g of a solid product obtained by lyophilization, water content of 2%) or by spray drying; if it is necessary to prepare a liquid product, the package can be sealed under inert gas protection. Example 1B
1000 克 (干重) 粉碎了的玉米麸皮, 加纯水配制为 5%的混合物后, 转 移到 10 升的压力反应釜内, 然后加入 50mM 的仿生催化剂 [CpFeCO (马来 酸)] BF4, 搅拌下将混合物加热到近 l OOoC并维持在此温度约 60分钟, 冷却 到室温后, 固液分离得到液体产品。  1000 g (dry weight) of crushed corn bran, mixed with pure water to prepare a 5% mixture, transferred to a 10 liter pressure reactor, and then added 50 mM biomimetic catalyst [CpFeCO (maleic acid)] BF4, The mixture was heated to near 100 ° C with stirring and maintained at this temperature for about 60 minutes. After cooling to room temperature, solid-liquid separation gave a liquid product.
液体产品通过 3cmx60cm的 XAD-4大孔吸附树脂柱, 流速 2毫升 /分钟, 所得的纤维戊糖水溶液中基本上检测不到催化剂, 然后调 pH为 5. 5 后加入 约 1. 5%豆饼粉, 121 oC灭菌 30分钟后加入 1%高效安琪酿酒干酵母, 34 oC 下发酵 24小时。 取样检测, HPLC分析方法六碳糖基本检测不到, 加热将酵 母灭活后, 过滤进行固液分离, 得液体产品。  The 5% of the bean cake powder is added after the 5% of the bean cake powder is added to the 5% of the bean cake powder. After sterilization for 30 minutes at 121 oC, 1% high-efficiency Anqi dry yeast was added and fermented at 34 °C for 24 hours. Sampling and detection, HPLC analysis method is basically undetectable. After the yeast is inactivated by heating, the solid-liquid separation is carried out by filtration to obtain a liquid product.
液体产品过离子交换(732-阳离子交换树脂柱、 721 -阴离子交换树脂柱、 和混床离子交换柱), 浓缩到含糖量(总糖含量, 使用阿贝折光仪)约为 50%, 其中阿拉伯糖的含量约为 53%, 总共得到的液体产品 (即纤维戊糖) 为 380  The liquid product is ion exchanged (732-cation exchange resin column, 721 - anion exchange resin column, and mixed bed ion exchange column), and concentrated to a sugar content (total sugar content, using an Abbe refractometer) of about 50%, wherein The arabinose content is about 53%, and the total liquid product (ie, fiber pentose) is 380.
实施例 2 Example 2
将冻干法制备的纤维戊糖固体产品 (即纤维戊糖 I )和微晶纤维素混合, 使微晶纤维素的含量为 10%、 20%、 30%、 40%, 用它们来喂食半岁大的猴子, 猴子的生活环境为人工控制的 12 小时白天 /12 小时夜晚, 室温为 24° C, 喂 食正常食品 7天后, 食品中被掺入加入微晶纤维素、 和没有加入微晶纤维素 的纤维戊糖, 使食物中含有阿拉伯糖的量分别为 20、 40、 60、 80克 /公斤饲 料, 收集动物的尿液分析其中的阿拉伯糖含量, 结果如下: 饲料含阿 微晶纤维素含 微晶纤维素含 微晶纤维素含 微晶纤维素含 微晶纤维素含 拉伯糖量 量 0 量 10% 量 20% 量 30% 量 40%The freeze-dried fiber pentose solid product (ie, fiber pentose I) and microcrystalline cellulose are mixed to make the content of microcrystalline cellulose 10%, 20%, 30%, 40%, and they are used to feed half. The old monkey, the monkey's living environment is manually controlled 12 hours day / 12 hours night, room temperature is 24 ° C, after feeding normal food for 7 days, the food is incorporated into the microcrystalline cellulose, and no microcrystalline fiber is added. The fiber pentose sugar, the amount of arabinose in the food is 20, 40, 60, 80 g / kg of feed, the urine of the collected animal is analyzed for the arabinose content, the results are as follows: Feed containing microcrystalline cellulose containing microcrystalline cellulose containing microcrystalline cellulose containing microcrystalline cellulose containing microcrystalline cellulose containing labo sugar amount 0 amount 10% amount 20% amount 30% amount 40%
20 10. 1 6. 3 4. 6 3. 3 1. 120 10. 1 6. 3 4. 6 3. 3 1. 1
40 12. 3 7. 5 5. 2 3. 8 1. 740 12. 3 7. 5 5. 2 3. 8 1. 7
60 14. 7 8. 2 5. 9 4. 3 1. 960 14. 7 8. 2 5. 9 4. 3 1. 9
80 15. 5 8. 9 6. 4 4. 9 2. 1 80 15. 5 8. 9 6. 4 4. 9 2. 1
(单位为百分比, 即食物中的阿拉伯糖有多少被排泄出来。 24小时内的排尿量) 结果表明, 未被吸收的阿拉伯糖被尿液排出, 其排出量随着微晶纤维素 含量的增高而减低。 实施例 3 (The percentage is the percentage of arabinose in the food that is excreted. The amount of urine in 24 hours.) The results show that the unabsorbed arabinose is excreted in the urine and its discharge increases with the amount of microcrystalline cellulose. And reduce. Example 3
通过与实施例 2相同的实验方案, 显示, 无微晶纤维素时, 使用维生素 B1 的量为 200毫克 /千克纤维戊糖时, 纤维戊糖的吸收可增加 16% ; 维生素 B5为 200毫克 /千克纤维戊糖时, 纤维戊糖的吸收可增加 21% ; 维生素 B6为 200毫克 /千克纤维戊糖时, 纤维戊糖的吸收可增加 1 1% ; 甲状腺素为 30毫 克 /千克纤维戊糖时, 纤维戊糖的吸收可增加 9% ; 肾上腺素为 20毫克 /千克 纤维戊糖时, 纤维戊糖的吸收可增加 1 1%; 钾离子为 200毫克 /千克纤维戊糖 时, 纤维戊糖的吸收可增加 27% ; 镁离子为 200毫克 /千克纤维戊糖时, 纤维 戊糖的吸收可增加 16% ; 钠离子为 200毫克 /千克纤维戊糖时, 纤维戊糖的吸 收可增加 6%。 实施例 4A  By the same experimental scheme as in Example 2, it was shown that when the amount of vitamin B1 was 200 mg/kg of fiber pentose without microcrystalline cellulose, the absorption of the fiber pentose sugar was increased by 16%; the vitamin B5 was 200 mg/ When gram of fiber pentose is used, the absorption of pentose can be increased by 21%; when vitamin B6 is 200 mg/kg of pentose, the absorption of pentose can be increased by 11%; when thyroxine is 30 mg/kg of pentose , the absorption of pentose can increase by 9%; when the adrenaline is 20 mg / kg of pentose, the absorption of pentose can increase by 11%; when the potassium ion is 200 mg / kg of pentose, the pentose Absorption can be increased by 27%; when magnesium ion is 200 mg/kg of fiber pentose, the absorption of pentose can be increased by 16%; when sodium ion is 200 mg/kg of pentose, the absorption of pentose can be increased by 6%. Example 4A
使用链脲佐菌素制备的 Π-型糖尿病鼠 9个星期大, 第一组为对照组, 6 只, 喂食纯蛋白食品、 并用二甲双胍控制血糖; 第二组蛋白饲料中使用实施 例 2中含微晶纤维素的纤维戊糖, 饲料中的阿拉伯糖含量为 80克 /公斤, 微 晶纤维素在纤维戊糖产品中的含量为 40%, 喂食三个月后, 测定 (从尾巴静 脉取血, 加入防凝剂后, 离心后得清液, 精密 pH 计测定) 它们血液的酸碱 度, 结果如下:
Figure imgf000011_0001
The sputum-type diabetic rats prepared with streptozotocin were 9 weeks old, the first group was the control group, 6 were fed with pure protein food, and metformin was used to control blood glucose; the second group of protein feed was used in Example 2 Fibrous pentose of microcrystalline cellulose, the arabinose content in the feed is 80 g/kg, and the content of microcrystalline cellulose in the fiber pentose product is 40%. After three months of feeding, the blood is taken from the tail vein. After adding the anti-coagulant, the supernatant is obtained by centrifugation, and the pH of the blood is measured by a precision pH meter. The results are as follows:
Figure imgf000011_0001
结果表明, 本发明中所揭示的产品, 可以有效防止糖尿病机体的酸化。 实施例 4B The results show that the product disclosed in the present invention can effectively prevent acidification of the diabetic body. Example 4B
在氮气保护下, 将冻干法制备的纤维戊糖固体产品 (即纤维戊糖 I ) 800 克, 加入到 3升的 95%的食用乙醇中, 然后加热回流, 慢慢加入约为 100毫 升的纯水, 回流约 10分钟后, 慢慢冷却到 20° C, 加入少量木糖晶种后, 此 温度下密封存放 24小时, 期间偶尔轻轻晃动。 24小时后, 冷却到零度 0° C, 置放 48小时, 过滤, 真空下干燥, 得 500克纯木糖, 纯度为 98. 6%。  Under the protection of nitrogen, the lyophilized fiber pentose solid product (ie, fiber pentose I) 800 g was added to 3 liters of 95% edible ethanol, then heated to reflux, and slowly added to about 100 ml. After pure water, reflux for about 10 minutes, slowly cool to 20 ° C, add a small amount of xylose seed crystals, and then store at this temperature for 24 hours, occasionally gently shaking. After 24 hours, the mixture was cooled to 0 ° C, and placed for 48 hours, filtered, and dried under vacuum to obtain 500 g of pure xylose with a purity of 98.6%.
使用链脲佐菌素制备的 Π-型糖尿病鼠 9个星期大, 第一组为对照组, 6 只, 喂食纯蛋白食品、 并用二甲双胍控制血糖; 第二组蛋白饲料中使用上述 制备的纯木糖, 饲料中的木糖含量为 120克 /公斤, 不含外加的微晶纤维素, 喂食三个月后, 测定 (从尾巴静脉取血, 加入防凝剂后, 离心后得清液, 精 密 pH计测定) 它们血液的酸碱度, 结果如下:
Figure imgf000012_0001
The sputum-type diabetic rats prepared with streptozotocin were 9 weeks old, the first group was the control group, 6 were fed with pure protein food, and metformin was used to control blood glucose; the second group of protein feed was prepared using the pure wood prepared above. Sugar, the xylose content in the feed is 120 g / kg, does not contain additional microcrystalline cellulose, after three months of feeding, determination (take blood from the tail vein, add anti-coagulant, centrifuge to obtain clear liquid, precision pH meter determination) The pH of their blood, the results are as follows:
Figure imgf000012_0001
结果显示, 纯的五碳糖也具备防止糖尿病体机体酸化的功能。 在本发明提及的所有文献都在本申请中引用作为参考, 就如同每一篇文 献被单独引用作为参考那样。 此外应理解, 在阅读了本发明的上述讲授内容 之后, 本领域技术人员可以对本发明作各种改动或修改, 这些等价形式同样 落于本申请所附权利要求书所限定的范围。  The results show that pure five-carbon sugar also has the function of preventing acidification of the body of the diabetic body. All documents mentioned in the present application are hereby incorporated by reference in their entirety in their entirety in their entireties in the the the the the the the the In addition, it is to be understood that various modifications and changes may be made to the present invention, and the equivalents of the scope of the present invention.

Claims

权 利 要 求 Rights request
1.一种纤维戊糖或含有纤维戊糖的组合物的用途, 其特征在于, 用于制 备预防和 /或治疗糖尿病患者机体酸化的食品或药物。 A use of a pentose pentose or a pentose-containing composition, which is for use in the preparation of a food or a medicament for preventing and/or treating acidification of a body of a diabetic patient.
2.如权利要求 1所述的用途, 其特征在于, 所述的含有纤维戊糖的组合 物由纤维戊糖和促进纤维戊糖在体内吸收的物质组成。  The use according to claim 1, wherein the fiber pentose-containing composition is composed of a fiber pentose sugar and a substance which promotes absorption of the fiber pentose sugar in the body.
3.如权利要求 2所述的用途, 其特征在于, 以 100重量份组合物计, 它 含有:  3. Use according to claim 2, characterized in that, based on 100 parts by weight of the composition, it contains:
1 一 100重量份纤维戊糖; 和  1 to 100 parts by weight of pentose sugar; and
0 - 99 重量份糖吸收促进剂; 所述的糖吸收促进剂选自下述的一种或多 种物质: 纤维素、 维生素 Bl、 维生素 B5、 维生素 B6、 甲状腺素、 肾上腺素、 钾离子、 镁离子、 钠离子。  0 - 99 parts by weight of a sugar absorption enhancer; the sugar absorption enhancer is selected from one or more of the following: cellulose, vitamin B1, vitamin B5, vitamin B6, thyroxine, adrenaline, potassium ion, Magnesium ions, sodium ions.
4.如权利要求 3所述的用途, 其特征在于, 所述纤维戊糖和糖吸收促进 剂的重量比为 0. 001— 1000: 1,较佳地为 0. 015— 10: 1,更佳地为 0. 02 - 0. 7: 1。  015—10: 1,更更优选。 0. 015—10: 1, more The best place is 0. 02 - 0. 7: 1.
5.如权利要求 3所述的用途, 其特征在于, 所述的纤维素包括所有的纤 维素, 优选微晶纤维素, 最优选纳米级的纤维素。  5. Use according to claim 3, characterized in that the cellulose comprises all cellulose, preferably microcrystalline cellulose, most preferably nano-sized cellulose.
6.如权利要求 1 一 4 任一所述的用途, 其特征在于, 所述的纤维戊糖选 自下述的一种或多种:木糖(xylose)、核糖(ribose)、阿拉伯糖(arab inose)、 来苏糖(lyxose)、 核酮糖(ribulose)、 木酮糖(xylulose)。  The use according to any one of claims 1 to 4, wherein the fiber pentose sugar is selected from one or more of the following: xylose, ribose, arabinose ( Arab inose), lyxose, ribulose, xylulose.
7.如权利要求 6所述的用途, 其特征在于, 所述的纤维戊糖以纤维戊糖 总重量计, 含有阿拉伯糖 1 一 90wt% ; 优选所述的纤维戊糖中含有阿拉伯糖 5 一 25wt%。  The use according to claim 6, wherein the fiber pentose contains 1 to 90% by weight of arabinose, based on the total weight of the fiber pentose; preferably, the fiber pentose contains arabinose 5 25wt%.
8.如权利要求 1 一 4 任一所述的用途, 其特征在于, 所述的纤维戊糖通 过以下步骤得到:  The use according to any one of claims 1 to 4, wherein the fiber pentose is obtained by the following steps:
( a )将含有纤维素的生物质和水混合, 在 20— 18CTC水解得到液体混合 物 I; 和  (a) mixing the cellulose-containing biomass with water and hydrolyzing at 20-18 CTC to obtain liquid mixture I;
( b ) 将液体混合物 I和酒精酵母在 20— 60 °C混合 6— 48小时后, 滤去 固体物, 浓缩得到纤维戊糖。  (b) After mixing the liquid mixture I and the alcohol yeast at 20-60 ° C for 6 to 48 hours, the solid matter is filtered off and concentrated to obtain a fiber pentose.
9.如权利要求 8所述的用途, 其特征在于, 所述的纤维戊糖通过以下步 骤得到:  The use according to claim 8, wherein the fiber pentose is obtained by the following steps:
( 1 ) 将含有纤维素的生物质、 水和催化剂在 30— 18CTC混合 3— 600分 钟, 水解得到液体混合物 I; 所述的催化剂选自: 半纤维素水解酶、 有机酸、 无机酸、 或仿生催化剂; 所述的有机酸选自: 含 20 个碳以下的有机酸; 所 述的无机酸选自: 硫酸、 盐酸、 磷酸; 所述的仿生催化剂选自 [CpFeCO (马来 酸)] BF4、 或乙二氨二乙酸铁络合物; (1) mixing the cellulose-containing biomass, water and catalyst at 30-18 CTC for 3 to 600 minutes, and hydrolyzing to obtain a liquid mixture I; the catalyst is selected from the group consisting of: hemicellulose hydrolase, organic acid, inorganic acid, or a biomimetic catalyst; the organic acid is selected from the group consisting of: an organic acid containing less than 20 carbons; the inorganic acid is selected from the group consisting of: sulfuric acid, hydrochloric acid, phosphoric acid; and the biomimetic catalyst is selected from the group consisting of [CpFeCO (Malay) Acid)] BF4, or iron diammonium diacetate complex;
(2) 将液体混合物 I和酒精酵母在 20— 60°C混合 6— 48小时, 得到液 体混合物 Π; 和  (2) mixing liquid mixture I and alcohol yeast at 20-60 ° C for 6 to 48 hours to obtain a liquid mixture Π;
(3) 液体混合物 II经过离子交换, 得到纤维戊糖。  (3) The liquid mixture II is ion-exchanged to obtain a fiber pentose.
10.如权利要求 8 所述的用途, 其特征在于, 所述的纤维戊糖通过以下 步骤得到:  The use according to claim 8, wherein the fiber pentose is obtained by the following steps:
(a)将含有纤维素的生物质和水混合, 在 90— 18CTC水解得到液体混合 物 I; 和  (a) mixing the cellulose-containing biomass with water and hydrolyzing at 90-18 CTC to obtain liquid mixture I;
(b)将液体混合物 I和酒精酵母在 20— 40°C混合 12— 48小时, 得到纤 维戊糖。  (b) Mixing the liquid mixture I and the alcohol yeast at 20-40 ° C for 12 to 48 hours to obtain a cellulose pentose.
11.如权利要求 8 所述的用途, 其特征在于, 所述的纤维戊糖通过以下 步骤得到:  The use according to claim 8, wherein the fiber pentose is obtained by the following steps:
(1)将含有纤维素的生物质、 水和催化剂在 90— 18CTC混合 30— 120分 钟, 水解得到液体混合物 I; 所述的催化剂选自: 半纤维素水解酶、 有机酸、 无机酸、 或仿生催化剂; 所述的有机酸选自: 含 20 个碳以下的有机酸; 所 述的无机酸选自: 硫酸、 盐酸、 磷酸; 所述的仿生催化剂选自: [CpFeCO (马 来酸)] BF4、 或乙二氨二乙酸铁络合物;  (1) The cellulose-containing biomass, water and catalyst are mixed at 90-18 CTC for 30-120 minutes, and hydrolyzed to obtain a liquid mixture I; the catalyst is selected from the group consisting of: hemicellulose hydrolase, organic acid, inorganic acid, or a biomimetic catalyst; the organic acid is selected from the group consisting of: an organic acid containing less than 20 carbons; the inorganic acid is selected from the group consisting of: sulfuric acid, hydrochloric acid, and phosphoric acid; and the biomimetic catalyst is selected from the group consisting of: [CpFeCO (maleic acid)] BF4, or iron diammonium diacetate complex;
(2)将液体混合物 I和酒精酵母在 20— 40°C混合 12— 48小时, 得到液 体混合物 Π; 和  (2) mixing liquid mixture I and alcohol yeast at 20-40 ° C for 12 to 48 hours to obtain a liquid mixture Π;
(3) 液体混合物 II经过离子交换, 得到纤维戊糖。  (3) The liquid mixture II is ion-exchanged to obtain a fiber pentose.
12.如权利要求 1 所述的用途, 其特征在于, 所述的食品包括固体食品 和液体食品。  The use according to claim 1, wherein the food product comprises a solid food and a liquid food.
13.—种从纤维素生物质制备纯木糖的方法, 其特征在于, 所述的方法 包括步骤: 将纤维戊糖经过简单的乙醇 /水混合溶剂重结晶;  13. A method of preparing pure xylose from cellulosic biomass, characterized in that the method comprises the steps of: recrystallizing the fiber pentose sugar through a simple ethanol/water mixed solvent;
所述的纤维戊糖通过以下步骤得到:  The fiber pentose is obtained by the following steps:
(1)将含有纤维素的生物质、 水和催化剂在 90— 18CTC混合 30— 120分 钟, 水解得到液体混合物 I; 所述的催化剂选自: 半纤维素水解酶、 有机酸、 无机酸、 或仿生催化剂; 所述的有机酸选自: 含 20 个碳以下的有机酸; 所 述的无机酸选自: 硫酸、 盐酸、 磷酸; 所述的仿生催化剂选自: [CpFeCO (马 来酸)] BF4、 或乙二氨二乙酸铁络合物;  (1) The cellulose-containing biomass, water and catalyst are mixed at 90-18 CTC for 30-120 minutes, and hydrolyzed to obtain a liquid mixture I; the catalyst is selected from the group consisting of: hemicellulose hydrolase, organic acid, inorganic acid, or a biomimetic catalyst; the organic acid is selected from the group consisting of: an organic acid containing less than 20 carbons; the inorganic acid is selected from the group consisting of: sulfuric acid, hydrochloric acid, and phosphoric acid; and the biomimetic catalyst is selected from the group consisting of: [CpFeCO (maleic acid)] BF4, or iron diammonium diacetate complex;
(2)将液体混合物 I和酒精酵母在 20— 40°C混合 12— 48小时, 得到液 体混合物 Π; 和  (2) mixing liquid mixture I and alcohol yeast at 20-40 ° C for 12 to 48 hours to obtain a liquid mixture Π;
(3) 液体混合物 II经过离子交换, 得到纤维戊糖。  (3) The liquid mixture II is ion-exchanged to obtain a fiber pentose.
PCT/CN2009/070959 2009-03-24 2009-03-24 Use of fiber pentose or composition containing fiber pentose in manufacture of foods or medicines for preventing and/or treating acidification in diabetic patient WO2010108314A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2009/070959 WO2010108314A1 (en) 2009-03-24 2009-03-24 Use of fiber pentose or composition containing fiber pentose in manufacture of foods or medicines for preventing and/or treating acidification in diabetic patient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2009/070959 WO2010108314A1 (en) 2009-03-24 2009-03-24 Use of fiber pentose or composition containing fiber pentose in manufacture of foods or medicines for preventing and/or treating acidification in diabetic patient

Publications (1)

Publication Number Publication Date
WO2010108314A1 true WO2010108314A1 (en) 2010-09-30

Family

ID=42780131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2009/070959 WO2010108314A1 (en) 2009-03-24 2009-03-24 Use of fiber pentose or composition containing fiber pentose in manufacture of foods or medicines for preventing and/or treating acidification in diabetic patient

Country Status (1)

Country Link
WO (1) WO2010108314A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2709464C2 (en) * 2015-09-29 2019-12-18 Кимберли-Кларк Ворлдвайд, Инк. Synergistic composition for maintaining healthy microflora balance

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1276212A (en) * 2000-06-01 2000-12-13 王敏 Functional oligose food
CN1366552A (en) * 2000-02-01 2002-08-28 尤尼蒂卡株式会社 Process for producing L-arabinose, L-arabinose-containing enzymatically processed products, diet foods, diabetic diet foods and fruit or vegetable juices and process for producing same
WO2004034960A2 (en) * 2002-10-21 2004-04-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel pentose derivatives as anti-hyperglycemic drugs
CN1629321A (en) * 2003-12-18 2005-06-22 中国科学院理化技术研究所 Process for extracting glucose and/or xylose for preparing ethanol by utilizing straw plants
CN101100685A (en) * 2007-08-01 2008-01-09 李萍 Method for preparing L-arabinose
CN101323870A (en) * 2008-07-25 2008-12-17 北京天地绿园农业科学研究院 Preparation of biofermentation xylitol and arabinose

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1366552A (en) * 2000-02-01 2002-08-28 尤尼蒂卡株式会社 Process for producing L-arabinose, L-arabinose-containing enzymatically processed products, diet foods, diabetic diet foods and fruit or vegetable juices and process for producing same
CN1276212A (en) * 2000-06-01 2000-12-13 王敏 Functional oligose food
WO2004034960A2 (en) * 2002-10-21 2004-04-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel pentose derivatives as anti-hyperglycemic drugs
CN1629321A (en) * 2003-12-18 2005-06-22 中国科学院理化技术研究所 Process for extracting glucose and/or xylose for preparing ethanol by utilizing straw plants
CN101100685A (en) * 2007-08-01 2008-01-09 李萍 Method for preparing L-arabinose
CN101323870A (en) * 2008-07-25 2008-12-17 北京天地绿园农业科学研究院 Preparation of biofermentation xylitol and arabinose

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2709464C2 (en) * 2015-09-29 2019-12-18 Кимберли-Кларк Ворлдвайд, Инк. Synergistic composition for maintaining healthy microflora balance
US11166968B2 (en) 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora

Similar Documents

Publication Publication Date Title
WO2003070148A1 (en) Granulation process
WO2013139111A1 (en) Total flavone extract of abelmoschus manihot and preparation method thereof
EP2589382A1 (en) Pharmaceutical composition comprising levocarnitine and dobesilate
JP2020537538A (en) Flavonoid extract of Gynura fusilier, and its preparation method and its use for treating hyperuricemia
CN104906121B (en) Pharmaceutical composition containing tylonolide
CN107536060A (en) A kind of method that low pressure humid heat treatment prepares amino acid modified corn slow-digestion starch
CN114366760A (en) Application of sargassum pallidum polyphenol in preparing medicine for treating diabetes and preparation method thereof
CN106617072A (en) Phytosterol compound lipid-decreasing formula and preparation method for tablet thereof
WO2021082311A1 (en) Pea peptide having supplementary blood glucose reducing function and preparation method therefor
CN109925287A (en) A kind of Pyrochep and preparation method thereof
WO2023061118A1 (en) Pharmaceutical composition for improving and treating leukotrichia and/or alopecia and preparation method therefor
WO2010108314A1 (en) Use of fiber pentose or composition containing fiber pentose in manufacture of foods or medicines for preventing and/or treating acidification in diabetic patient
WO2012140894A1 (en) Pharmaceutical composition
CN114848699B (en) Composition with uric acid reducing effect and preparation method and application thereof
JP2021512997A (en) Separated windproof polysaccharides and their uses
CN113100320B (en) Walnut oligopeptide candy with function of relieving sub-health fatigue and preparation method thereof
CN107550896A (en) A kind of alliin composition
CN107114775B (en) Blood fat reducing compound based on swim bladder polypeptide of miichthys miiuy and preparation method thereof
CN1081032C (en) Medicinal preparation containing saccharin zinc
CN101507728B (en) Composite for preventing and treating body acidification of diabetic
JP4232461B2 (en) Atopic dermatitis improving agent
WO2024040630A1 (en) Composition for controlling blood glucose, preparation method therefor, and use of same in reducing gi value of foods
CN113995798B (en) Preparation method of lycium ruthenicum anthocyanin extract and freeze-dried powder and application of lycium ruthenicum anthocyanin extract and freeze-dried powder in products for resisting gouty arthritis and reducing uric acid
JPH0131487B2 (en)
CN1303979C (en) Preparation of snake gallbladder and tangerine peel dispersed tablets

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09842051

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09842051

Country of ref document: EP

Kind code of ref document: A1